What is Angioslide?
Founded in 2005 by Eran Hirszowicz and Amos Nahir, Angioslide is a privately-held medical device firm focused on delivering cost-effective, innovative solutions for emboli management during vascular interventions. The company's PROTEUS device family is recognized as the sole FDA-cleared product capable of capturing and removing embolic particles dislodged at the lesion site in peripheral arteries. This specialization positions Angioslide as a key player in enhancing patient safety and procedural outcomes within interventional cardiology and radiology.
How much funding has Angioslide raised?
Angioslide has raised a total of $24.9M across 3 funding rounds:
Series A
$4M
Series B
$14.6M
Series C
$6.3M
Series A (2006): $4M with participation from Viola Partners
Series B (2013): $14.6M led by Triventures, Ofer-Hi Tech, and Agate Medical investments
Series C (2013): $6.3M supported by TriVentures and Viola Partners
Key Investors in Angioslide
TriVentures
TriVentures is a global venture capital fund that invests in early-stage companies with innovative breakthroughs in healthcare and other industries. The firm focuses on bio-convergence and data-driven technologies, partnering with exceptional entrepreneurs to drive transformative solutions.
Viola Partners
Viola Group is Israel's leading technology investment group, managing over $6 billion in assets. The firm supports Israeli entrepreneurs in building transformational technology companies through its multi-strategy investment approach.
Ofer-Hi Tech
Undisclosed investor participating in the funding round.
What's next for Angioslide?
The substantial enterprise-level funding context suggests Angioslide is poised for significant scaling and market expansion. This strategic investment will likely fuel further research and development, enhance manufacturing capabilities, and broaden the commercial reach of its PROTEUS device family. The company's focus on innovative emboli management solutions indicates a trajectory towards solidifying its market leadership and potentially exploring new therapeutic areas within vascular interventions.
See full Angioslide company page
